Barinthus Biotherapeutics plc (BRNS) - Total Liabilities
Based on the latest financial reports, Barinthus Biotherapeutics plc (BRNS) has total liabilities worth $24.64 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore BRNS operating cash flow to assess how effectively this company generates cash.
Barinthus Biotherapeutics plc - Total Liabilities Trend (2019–2024)
This chart illustrates how Barinthus Biotherapeutics plc's total liabilities have evolved over time, based on quarterly financial data. See net assets of Barinthus Biotherapeutics plc for net asset value and shareholders' equity analysis.
Barinthus Biotherapeutics plc Competitors by Total Liabilities
The table below lists competitors of Barinthus Biotherapeutics plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Carimin Petroleum Bhd
KLSE:5257
|
Malaysia | RM136.26 Million |
|
Starteck Finance Limited
NSE:STARTECK
|
India | Rs3.22 Billion |
|
Morgan Sindall Group PLC
LSE:MGNS
|
UK | GBX1.57 Billion |
|
Vikas EcoTech Limited
NSE:VIKASECO
|
India | Rs883.31 Million |
|
White Horse Bhd
KLSE:5009
|
Malaysia | RM121.98 Million |
|
Hotel Royal Chihpen
TWO:5704
|
Taiwan | NT$129.10 Million |
|
Cue Biopharma
NASDAQ:CUE
|
USA | $18.40 Million |
|
Ohmyhome Limited Ordinary Shares
NASDAQ:OMH
|
USA | $4.26 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Barinthus Biotherapeutics plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BRNS market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Barinthus Biotherapeutics plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Barinthus Biotherapeutics plc (2019–2024)
The table below shows the annual total liabilities of Barinthus Biotherapeutics plc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $30.19 Million | +9.75% |
| 2023-12-31 | $27.51 Million | +1.88% |
| 2022-12-31 | $27.00 Million | -4.08% |
| 2021-12-31 | $28.15 Million | -47.68% |
| 2020-12-31 | $53.81 Million | +30.86% |
| 2019-12-31 | $41.12 Million | -- |
About Barinthus Biotherapeutics plc
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targetin… Read more